Ruxolitinib in adult dermatomyositis with anti-TIF1γ antibody: a case report and literature review

Front Immunol. 2025 Jun 12:16:1591631. doi: 10.3389/fimmu.2025.1591631. eCollection 2025.

Abstract

Ruxolitinib is a selective JAK1/2 inhibitor, and its application in treating adult-onset dermatomyositis(DM) has rarely been described. Here, we report a case of an adult-onset DM patient with anti-TIF1γ antibody, who also suffered from essential thrombocytosis related to the JAK2 V617F mutation. Her clinical symptoms of DM markedly improved after ruxolitinib treatment, whereas her platelet count did not significantly change. In addition, we reviewed previous studies on the treatment of adult DM with ruxolitinib, and summarized reports of the JAK2 V617F mutation in adult idiopathic inflammatory myopathy.

Keywords: JAK2 V617F mutation; anti-TIF1γ antibody; dermatomyositis; essential thrombocytosis; ruxolitinib.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Autoantibodies* / blood
  • Autoantibodies* / immunology
  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / drug therapy
  • Dermatomyositis* / immunology
  • Female
  • Humans
  • Janus Kinase 2 / genetics
  • Middle Aged
  • Mutation
  • Nitriles
  • Pyrazoles* / therapeutic use
  • Pyrimidines
  • Transcription Factors* / immunology
  • Treatment Outcome

Substances

  • Pyrazoles
  • ruxolitinib
  • Nitriles
  • Pyrimidines
  • TRIM33 protein, human
  • Janus Kinase 2
  • Transcription Factors
  • Autoantibodies
  • JAK2 protein, human